Navigation Links
Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
Date:4/27/2009

Trial Will Build on Pivotal Phase III Study for the Treatment of Advanced Prostate Cancer

PARSIPPANY, N.J., April 27 /PRNewswire/ -- Ferring Pharmaceuticals announced today the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. The announcement was made at the 2009 American Urological Association Annual Meeting in Chicago, IL.

The Phase IIIB trial will investigate the use of degarelix for intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies. The study will compare IADT to continuous androgen deprivation therapy (ADT) for 14 months with either leuprolide or degarelix. The trial evaluates whether IADT minimizes the negative effects of ADT and maximizes quality of life, while maintaining tumor response as measured by PSA suppression.

"Intermittent androgen deprivation therapy is a commonly employed treatment for men with biochemical failure, however it needs to be evaluated in a randomized clinical trial," says Dr. E. David Crawford, Head Urologic Oncology, University of Colorado, Denver and a trial investigator. "There is potential value in combining the rapid, sustained suppression of testosterone that degarelix offers in this treatment. IADT appears to improve patient quality of life and that will also be evaluated."

Physicians interested in serving as trial investigators should call 1-973-796-1600 to speak with Ferring Pharmaceuticals' Medical Information office.

Degarelix Phase III Trials

Phase III pivotal studies showed that degarelix is as effective as leuprolide (Lupron Depot(R))(*)in reducing and sustaining castrate levels
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Oct. 18, 2011 Phreesia, the patient check-in ... of electronic health records (EHR) software and solutions, ... Through this partnership, medical practices nationwide that use ... achieve a seamless patient check-in experience. The automated ...
... Melnik, President & CEO of PediaVisionJeff Mortensen, Vice President ... a revolutionary new vision screening device, which identifies vision ... October 20, Friday October 21 WHY: Spot is ... children across America.   Spot has an incredibly ...
Cached Medicine Technology:Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 2Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 3
(Date:7/10/2014)... known as the "Mississippi baby" an infant seemingly cured ... a prolonged remission of HIV infection in The New ... of HIV after more than two years of not taking ... HIV specialist and researchers involved in the case. ... this young child, the medical staff involved in the child,s ...
(Date:7/10/2014)... those students looking to bump up their grade point ... more time in a library or study hall, but ... shows that students who were members of the recreational ... freshman and sophomore years had higher GPAs than those ... students with memberships stayed in school longer. An increase ...
(Date:7/10/2014)... ROCHESTER, Minn. The benefits of medical imaging far ... ordered The Right Way, with The Right Radiation Dose. ... ratio and Mayo Clinic is leading a collaborative effort ... The commentary, published online in the Journal of ... Radiology, the Joint Commission, the Intersociety Accreditation Commission, and ...
(Date:7/10/2014)... illness and even death are likely to result if ... Now, however, a team of researchers based at The ... order of infection, the bacteria Streptococcus pneumoniae ... case of the flu. , The researchers discovered ... a bacterial virulence factor, might protect macrophagesa type of ...
(Date:7/10/2014)... A neuroscientist at Rutgers University-Newark says the human brain ... a finding that could provide a better understanding ... conditions that afflict an estimated 13.6 million Americans. , ... , Michael Cole, an assistant professor at the Center ... brain architecture of a person at rest is basically ...
Breaking Medicine News(10 mins):Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:Want a higher GPA in college? Join a gym 2Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:Working to loosen the grip of severe mental illness 2
... Authentidate Holding Corp. (Nasdaq: ADAT ), ... workflow management services, today announced financial results for the ... Benjamin, President of Authentidate, stated, "Revenue growth slowed during ... conditions impacted our results. Although total revenues were ...
... of the most harmful forms of teen drug abuse with a hard-hitting ... ... Los Angeles, CA (PRWEB) February 12, 2009 -- Statistics show a dangerous ... office of the DEA announced this week that Phoenix high school students ...
... An investor group in Trinity,Biotech plc (Nasdaq: ... of,diagnostic products, is delighted that Jim Merselis has joined ... support for Mr. Merselis, the,group has scheduled a conference ... am PT) on Tuesday, February 17, 2009. , ...
... advancing the lives,of children and adults experiencing barriers to ... hit the slopes last weekend. Nearly,200 community members, volunteers ... a day of fun, competition and meeting new friends ... The event, at Trollhaugen in Dresser, ...
... SCAN Long Term Care and SCAN Health Plan Arizona, ... of Health Plans. "The new association intends to be ... here in Arizona," said Lescault. "As president I look ... the governor,s office in adjusting the state health budget ...
... CRANBURY, N.J., Feb. 12 Innophos Holdings, Inc. (Nasdaq: ... in North America, today announced the election of John ... is Executive Vice President and Chief Operating Officer of ... of highly engineered specialty chemicals, including polymer additives, catalysts ...
Cached Medicine News:Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 2Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 3Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 4Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 5Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 6Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 7Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 8Health News:Church of Scientology Fighting Teen Drug Abuse 2Health News:Second Annual Courage Cup Race Raises More Than $5,000 for Courage Center's Ski and Snowboard Program 2Health News:SCAN's Thomas Lescault Elected President of New Arizona Association of Health Plans 2Health News:Innophos Holdings, Inc. Elects John M. Steitz as New Independent Director 2
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
The MediLive ImageBox is the first, easy-to-use digital,recording device that integrates with the surgical microscope and video camera., ,It simplifies image capturing by burning the still imag...
With MediLive MindStream you can make, cut and edit digital videos, add commentaries and notes, and save them. MediLive MindStream - intuitive user interface and high-resolution monitor all in one....
... non-mydriatic fundus camera increases ... of fundus imaging. Compact, ... set the standard in ... a unique combination of ...
Medicine Products: